Search

Displaying results 4711 - 4720 of 6835 in total
  1. Drug

    TTAX01

    go.drugbank.com/drugs/DB17928
    Investigational

    TTAX01 is a cryopreserved human umbilical cord product being developed by TissueTech.[L47246]

  2. Drug

    Trapidil

    go.drugbank.com/drugs/DB09283
    Experimental

    Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney

  3. Drug

    NN344

    go.drugbank.com/drugs/DB05115
    Experimental

    NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile.

  4. Drug

    Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins

    go.drugbank.com/drugs/DB15729
    Investigational

    This is followed by purification and expansion of the cells in vitro.

  5. Drug

    L-Acetylleucine

    go.drugbank.com/drugs/DB16956
    ApprovedInvestigational

    as neuroprotective disease-modifying effect of the DL-form of N-acetylleucine, after which animal studies showed that the L-enantiomer (i.e. levacetylleucine) has potential clinical benefits compared to

  6. Drug

    Spinosad

    go.drugbank.com/drugs/DB08823
    ApprovedVet approved

    Spinosad has also been experimented for use in cats for treatment of flea infestations, and has also been experimented for use against the KS1 Ctenocephalides felis flea strain infesting dogs, in addition to

  7. Drug

    Flutamide

    go.drugbank.com/drugs/DB00499
    ApprovedInvestigational

    An antiandrogen with about the same potency as cyproterone in rodent and canine species.

  8. Drug

    Silver sulfadiazine

    go.drugbank.com/drugs/DB05245
    ApprovedInvestigationalVet approved

    Silver sulfadiazine is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns.

  9. Drug

    Fasedienol

    go.drugbank.com/drugs/DB04968
    Investigational

    PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder).

  10. Drug

    SynOV1.1

    go.drugbank.com/drugs/DB17539
    Investigational

    SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. … It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF).